Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, October 12, 2016
Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016
Tuesday, October 4, 2016
Exclusive Licensing Agreement for In-house Developed Monoclonal Antibody Farletuzumab in Latin America Concluded with Eurofarma Laboratorios S.A.
Launch of Uritos Tablets for Overactive Bladder in Thailand
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States
Friday, September 30, 2016
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma
Thursday, September 29, 2016
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016
Wednesday, September 28, 2016
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis
Eisai Commences Provision of "EMILY" Smartphone App to Support Living with Epilepsy in Japan
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa
Thursday, September 15, 2016
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: